Analysts See $0.41 EPS for QIAGEN N.V. (QGEN); Gentex (GNTX) Shorts Decreased By 7.42%

January 15, 2018 - By Dolores Ford

Gentex Corporation (NASDAQ:GNTX) had a decrease of 7.42% in short interest. GNTX’s SI was 15.92 million shares in January as released by FINRA. Its down 7.42% from 17.19 million shares previously. With 1.72M avg volume, 9 days are for Gentex Corporation (NASDAQ:GNTX)’s short sellers to cover GNTX’s short positions. The SI to Gentex Corporation’s float is 5.66%. The stock increased 1.50% or $0.34 during the last trading session, reaching $23. About 2.48M shares traded or 30.56% up from the average. Gentex Corporation (NASDAQ:GNTX) has risen 19.63% since January 15, 2017 and is uptrending. It has outperformed by 2.93% the S&P500.

Analysts expect QIAGEN N.V. (NYSE:QGEN) to report $0.41 EPS on February, 7.They anticipate $0.02 EPS change or 5.13% from last quarter’s $0.39 EPS. QGEN’s profit would be $92.81M giving it 19.91 P/E if the $0.41 EPS is correct. After having $0.32 EPS previously, QIAGEN N.V.’s analysts see 28.13% EPS growth. The stock increased 1.43% or $0.46 during the last trading session, reaching $32.65. About 723,291 shares traded. QIAGEN N.V. (NYSE:QGEN) has risen 54.62% since January 15, 2017 and is uptrending. It has outperformed by 37.92% the S&P500.

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company has market cap of $7.39 billion. It offers sample technologies for plasmid deoxyribonucleic acid purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technology solutions. It has a 85.47 P/E ratio. The firm provides Ingenuity Variant Analysis, a cloud platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products.

Among 7 analysts covering Gentex Corp (NASDAQ:GNTX), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Gentex Corp had 17 analyst reports since October 20, 2015 according to SRatingsIntel. The stock of Gentex Corporation (NASDAQ:GNTX) has “Neutral” rating given on Wednesday, January 27 by Robert W. Baird. The company was maintained on Thursday, January 11 by FBR Capital. KeyBanc Capital Markets maintained it with “Buy” rating and $25.0 target in Thursday, October 12 report. On Friday, October 21 the stock rating was maintained by FBR Capital with “Outperform”. As per Wednesday, August 23, the company rating was maintained by KeyBanc Capital Markets. Robert W. Baird maintained Gentex Corporation (NASDAQ:GNTX) rating on Monday, October 23. Robert W. Baird has “Outperform” rating and $21 target. The stock of Gentex Corporation (NASDAQ:GNTX) earned “Buy” rating by FBR Capital on Tuesday, January 2. FBR Capital maintained Gentex Corporation (NASDAQ:GNTX) rating on Wednesday, July 19. FBR Capital has “Buy” rating and $2500 target. The stock has “Buy” rating by Robert W. Baird on Friday, October 20. The rating was maintained by KeyBanc Capital Markets on Monday, November 13 with “Buy”.

Since August 7, 2017, it had 0 insider purchases, and 3 selling transactions for $4.39 million activity. Downing Steven R sold $157,582 worth of stock or 8,000 shares. On Wednesday, September 27 the insider Nash Kevin C sold $85,094. On Monday, August 7 BAUER FRED sold $4.15 million worth of Gentex Corporation (NASDAQ:GNTX) or 239,400 shares.

Investors sentiment increased to 1.24 in 2017 Q3. Its up 0.32, from 0.92 in 2017Q2. It is positive, as 35 investors sold Gentex Corporation shares while 109 reduced holdings. 41 funds opened positions while 137 raised stakes. 224.48 million shares or 0.88% less from 226.47 million shares in 2017Q2 were reported. Burgundy Asset Ltd owns 11.18M shares for 2.1% of their portfolio. 1,300 are held by Bartlett Lc. Fiduciary Trust has invested 0.01% of its portfolio in Gentex Corporation (NASDAQ:GNTX). Great Lakes Advisors Ltd Llc, a Illinois-based fund reported 122,201 shares. 1.30M were reported by Provident Management. South Dakota Inv Council reported 0.06% stake. Balyasny Asset Mngmt Ltd Limited Liability Company reported 42,715 shares. Teacher Retirement Of Texas accumulated 23,728 shares. 53,582 are held by Old Natl Comml Bank In. Spectrum Mgmt Grp stated it has 0% of its portfolio in Gentex Corporation (NASDAQ:GNTX). Citadel Advsrs Limited Liability Company invested 0% of its portfolio in Gentex Corporation (NASDAQ:GNTX). Deutsche Retail Bank Ag accumulated 0.01% or 434,037 shares. Amalgamated Bancorp has 55,493 shares. Inv Counselors Of Maryland Ltd Liability holds 131,176 shares or 0.13% of its portfolio. Credit Agricole S A, a France-based fund reported 79,287 shares.